IT Versione italiana

press conferences » Retinal diseases: the CATT Study and the emerging treatments

A difficult choice: lower costs vs. fewer side effects

From 16.05.2012 to 16.05.2012    Milano, Circolo della Stampa

The Novartis press conference addresses issues related to the treatment of degenerative diseases of the macula and retinal diseases and their impact on the quality of life.  The CATT Study compares two different molecules (ranibizumab and bevacizumab), and focuses on the different side effects.



Cookies helps us to provide our services. Using these services , you agree to use of cookies on our part. OK